Certolizumab pegol – Tumor necrosis factor inhibitor for refractory uveitis

PURPOSE: The purpose of our study is to report our experience with the use of certolizumab pegol in patients with refractory non-infectious uveitis. OBSERVATIONS: We present a case series of three patients with non-infectious uveitis, treated with twice-monthly subcutaneous certolizumab pegol. All o...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharon, Yael, Chu, David S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068621/
https://www.ncbi.nlm.nih.gov/pubmed/32190782
http://dx.doi.org/10.1016/j.ajoc.2020.100633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068621/
https://www.ncbi.nlm.nih.gov/pubmed/32190782
http://dx.doi.org/10.1016/j.ajoc.2020.100633

Ejemplares similares